Nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation [ID1582]
Discontinued
Reference number: GID-TA10495
The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation.
Please note that following on from advice received from the company the timelines for this appraisal are currently to be confirmed.
As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties as and when the situation changes.